GlassScriptPhysician profile
Khizer S Shaikh
NPI 1255560884
$2,646.89
in general payments reported to CMS, 2019-2025
24 companies · $401 in 2025
The $401 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2020: $443 · 2021: $462 · 2022: $238 · 2023: $275 · 2024: $562 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,238.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $459.11 | 2019-2025 | Tezspire, Imfinzi, Airsupra |
| Merck Sharp & Dohme LLC | $388.86 | 2022-2025 | Winrevair, Keytruda |
| Actelion Pharmaceuticals US, INC. | $365.12 | 2019-2024 | Opsumit |
| Glaxosmithkline, LLC. | $303.76 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Baxter Healthcare | $226.08 | 2022-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care, Hillrom - Volara System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.24 | 2019-2024 | Ofev |
| Edwards Lifesciences Corporation | $160.38 | 2024 | Sapien 3 Ultra Resilia |
| Medtronic, INC. | $129.99 | 2021 | |
| United Therapeutics Corporation | $90.20 | 2021-2024 | Tyvaso |
| Mylan Specialty L.P. | $82.83 | 2021-2024 | Yupelri |
| Philips North America LLC | $54.66 | 2020-2021 | |
| Grifols USA, LLC | $32.11 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $19.45 | 2019 | |
| Veran Medical Technologies, INC. | $18.56 | 2020 | |
| Covidien LP | $18.50 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $18.38 | 2024 | Monarch Platform |
| Abiomed | $16.46 | 2024 | Impella |
| Advanced Respiratory, INC | $16.40 | 2020 | |
| Sunovion Pharmaceuticals INC. | $14.85 | 2019 | |
| Genzyme Corporation | $13.49 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $13.43 | 2024 | Dupixent |
| Gilead Sciences, INC. | $12.91 | 2021 | |
| Electromed, INC. | $12.50 | 2021 | |
| Boston Scientific Corporation | $11.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khizer Shaikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.